Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Breast cancer is the most frequently diagnosed cancer in women, with estrogen receptor
positive (ER+) breast cancer making up approximately 75% of all breast cancers diagnosed …

Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

Endocrine therapy (ET) is a pivotal strategy to manage early-and advanced-stage estrogen
receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC) …

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-
positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive …

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy
in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations …

Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for
activation. Mutations that constitutively activate ERα without the need for hormone binding …

Introduction The selective estrogen receptor degrader (SERD) and full receptor antagonist
provides an important therapeutic option for hormone receptor (HR)-positive breast cancer …

Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …

Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast
cancer. Despite the development of several effective therapies targeting ERα signaling …